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Objective: To evaluate toxicity and patterns of radiologic
lung injury on CT images after hypofractionated image-
guided stereotactic body radiotherapy (SBRT) delivered
with helical tomotherapy (HT) in medically early stage
inoperable non-small-cell lung cancer (NSCLC).
Methods: 28 elderly patients (31 lesions) with compromised
pulmonary reserve were deemed inoperable and enrolled to
undergo SBRT. Patterns of lung injury based on CT
appearance were assessed at baseline and during follow
up. Acute (6 months or less) and late (more than 6 months)
events were classified as radiation pneumonitis and radia-
tion fibrosis (RF), respectively.
Results: After a median follow-up of 12 months (range,
4–20 months), 31 and 25 lesions were examined for acute
and late injuries, respectively. Among the former group,
25 (80.6%) patients showed no radiological changes. The
CT appearance of RF revealed modified conventional,
mass-like and scar-like patterns in three, four and three
lesions, respectively. No evidence of late lung injury was
demonstrated in 15 lesions. Five patients developed
clinical pneumonitis (four patients, grade 2 and one
patient, grade 3, respectively), and none of whom had
CT findings at 3 months post-treatment. No instance of
symptomatic RF was detected. The tumour response rate
was 84% (complete response1partial response). Local
control was 83% at 1 year.
Conclusion: Our findings show that HT-SBRT can be
considered an effective treatment with a mild toxicity
profile in medically inoperable patients with early stage
NSCLC. No specific pattern of lung injury was
demonstrated.
Advances in knowledge: Our study is among the few
showing that HT-SBRT represents a safe and effective
option in patients with early stage medically inoperable
NSCLC, and that it is not associated with a specific
pattern of lung injury.
Surgery is the standard treatment for early stage non-small-
cell lung cancer (NSCLC), with an overall survival of about
50–70% in Stage I patients.1 In clinical practice, however,
patients with lung tumours, primary or metastatic, often
present with related symptoms, advanced age and associ-
ated comorbid conditions. Unfortunately, most of them are
excluded from clinical trials that are designed to inform
practice, creating major evidence gaps. This clinical sce-
nario is expected to further increase the number of cases in
the elderly,2,3 with the consequence that, if untreated, the
survival rates of these patients can be severely poor.4
Tackling this population represents a therapeutic challenge,
and new opportunities exist to improve the management
and outcomes for elderly people with coexisting ill-
nesses. In previous years, there has been much evidence
of good outcomes obtained with stereotactic body ra-
diotherapy (SBRT) for primary tumours or metastases in
the lung for inoperable patients,5–8 and the introduction
of SBRT has improved population-based survival in
Stage I NSCLC.9,10
Among the various treatment delivery units, helical
tomotherapy (HT) is a kind of image-guided system that is
able to deliver intensity-modulated radiation therapy
(IMRT) by combining a continuously rotating fan beam
with synchronous couch movement.11,12 While dosimetric
findings have shown that such capabilities can potentially translate
into the delivery of an increased tumour dose with doses to normal
tissues decreased compared with other techniques,13,14 only
a limited number of patients were included in recent studies that
have addressed the feasibility of hypofractionated or ablative RT
regimens for lung tumours treated with HT.15–21 The helical ra-
diation delivery method is associated with low-dose spread12 to the
normal lung and can potentially result in patterns of lung injury
that might be different than those observed with conventional
three-dimensional conformal RT (3D-CRT) or other SBRT tech-
niques. These latter issues raise some concerns, especially in elderly
patients, with frailties or comorbidities, given the risk that the
potential benefits of SBRTmight be hampered by an increased risk
of toxicity that can be life threatening or at least substantially
compromise their quality of life.
The aim of the present study is to evaluate treatment-related
toxicity and patterns of radiologic lung injury on CT images
after image-guided SBRT delivered with HT (HT-SBRT) for
patients with early stage medically inoperable NSCLC.
METHODS AND MATERIALS
Patients’ characteristics
28 patients with early stage NSCLC were deemed inoperable
from our thoracic oncology tumour board owing to advanced
age and/or a compromised pulmonary reserve and were enrolled
to undergo SBRT. Patients had to adhere to the following
characteristics: maximum tumour diameter ,50mm; advanced
age (75 years or more) and/or a diagnosis of severe chronic
obstructive pulmonary disease (COPD), categorized according
to the Global Initiative for Obstructive Lung Disease (GOLD)
guidelines;22 life expectancy of more than 6 months; perfor-
mance status (Eastern Cooperative Oncology Group Criteria),
0–2; no prior thoracic irradiation; no other simultaneous ma-
lignancies; and no restrictions on previous chemotherapy. Most
patients had a whole-body fluorine-18 fludeoxyglucose (18F-FDG)
positron emission tomography (PET) scan. A confirmed histo-
logical diagnosis was obtained for 22 (79%) patients. The pre-
treatment and follow-up CT scans and clinical records were
retrospectively reviewed, with the approval obtained from our
institutional review board. Written informed consent was
obtained from all patients.
Treatment
All patients were positioned supine on a wing board and
immobilized by means of thermoplastic frames. Two series of
CT scans were acquired in the inspiratory and expiratory phases,
at 3-mm slice thickness, in order to track the motion of tumours
and internal organs. We defined gross tumour volume (GTV)
through the superimposition of each visible tumour on two
series of CT scans delineated with the lung CT window setting
(window level52550HU, width5 1600HU) to obtain an in-
ternal target volume (ITV). The planning target volume (PTV)
was created by expanding the ITV by a uniform 5-mmmargin to
compensate for set-up errors and residual respiratory motion.
Overall, the median PTV was 47.31 cm3 (range, 9.4–254.5 cm3),
and the median GTV was 6.43 cm3 (range, 0.65–73.70 cm3). The
choice of radiation schedule was based on a risk-adapted
strategy, on target volume and type/site of lesion. The biological
effective dose (BED10) was $100Gy in 22 peripheral lesions,
where the total prescribed dose was 50Gy/5 fractions and
was ,100Gy in 4 peripheral large lesions (volume, .90 cm3)
and 5 centrally located lesions, which received a total prescribed
dose of 50Gy/10 fractions and 52.5Gy/7 fractions, respectively
(Table 1). The optimization was driven with the aim of de-
livering the prescribed dose to at least 95% of the PTV, while
keeping the maximum dose (Dmax) to the PTV ,105% of the
prescribed dose with heterogeneity corrections. Specific dosi-
metric guidelines for organs at risk (OARs) in accordance to
the QUANTEC23 dose–volume model were applied. Dose
computation and treatment delivery were performed on the
TomoTherapy® Hi-Art® II System (TomoTherapy Inc., Madi-
son, WI). Image-guided radiotherapy (RT) was performed by
means of megavolt CT before each daily fraction. The delivery
parameters usually adopted for treatment planning and opti-
mization were field width, 2.5 cm; pitch, 0.287; modulation
factor, 2.5; dose calculation grid, 0.2153 0.215 cm.
Follow-up and statistics
Routine patient follow-up consisted of outpatient assessments
performed 1 month post-SBRT (physical examination1 chest
radiography) and every 3 months in the next 2 years, alternating
a quarterly diagnostic CT scan of the thorax and upper abdomen
with a semi-annually total body CT scan. A post-treatment
18F-FDG/PET-CTwas routinely carried out between 4 and 6 months
after treatment completion and for suspected progressive dis-
ease. Toxicity monitoring was focused on treatment-related
pulmonary adverse events according to the Common Termi-
nology Criteria for Adverse Events v. 4.0:24 grade 1 (asymp-
tomatic or requiring no treatment), grade 2 [symptomatic,
requiring medical intervention or limiting instrumental active
daily life (ADL)], grade 3 (severely symptomatic, limiting self
care and ADL, or oxygen indicated), grade 4 [life threatening,
respiratory compromise, urgent intervention indicated
(e.g. tracheostomy or intubation)] and grade 5 (death). Any
increase in grade from baseline was considered treatment-
related toxicity and graded as acute (90 days from start of RT)
and late (beyond 90 days).
Patterns of lung injury were based on CT findings and consid-
ered as radiation pneumonitis (RP) or radiation fibrosis (RF),
when they occurred within or later than 6 months, respectively.
RP was classified into five patterns based on Ikezoe’s report:25
(1) diffuse consolidation, (2) patchy consolidation and ground-
glass opacities (GGOs), (3) diffuse GGO, (4) patchy GGO and
(5) no evidence of increased density. RF was graded according to
Koenig’s classification26 as follows: (1) modified conventional
pattern (consolidation, volume loss and bronchiectasis similar
to, but less extensive than, conventional RF), (2) mass-like
pattern (focal consolidation limited around the tumour),
(3) scar-like pattern (linear opacity in the region of the
tumour associated with volume loss).
Assessment of tumour response was based on the European
Organization for Research and Treatment of Cancer Response
Evaluation Criteria in Solid Tumours criteria v. 1.1,27 coupled
with a 18F-FDG/PET-CT scan whenever CT findings alone were
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uncertain. Local failure (LF) was defined as re-growth of the
disease within or at the margin of the PTV, whereas recurrence
in the ipsilateral/contralateral lung or extrathoracic sites was
defined as distant failure (DF).
Subgroups were compared with the log-rank test in order to find
potential predictive factors. The Fisher exact test (n, 5) or the
x2 test was used to determine predictive factors for lung fibrosis
and clinical response. Parameters evaluated as potential pre-
dictive factors for type of response were tumour-related factors
and BED. Parameters evaluated as potential predictive factors for
RP or lung fibrosis were dosimetric parameters [percentage of
lung volume receiving 5Gy (V5), percentage of lung volume
receiving 10Gy (V10), mean lung dose (MLD), contralateral
MLD], tumour-related factors, BED and COPD. Statistical
analysis was performed using the SPSS® statistical software
package v. 22 (IBM Corporation, Armonk, NY).
RESULTS
Toxicity rates and lung injury patterns
This study included 28 patients with 31 lesions treated between
January 2012 and January 2014. The median follow-up time was
12 months (range, 4–20 months). 30- and 90-day mortality rates
were 0%. Grade 1 acute oesophagitis was observed in two (7%)
patients; one of these patients had a centrally located tumour.
Overall, RP occurred 3 months after the completion of RT; one
(3.5%) patient experienced a clinically severe (grade 3) pneu-
monitis, while grade 2 RP was observed in four (14%) patients.
No correlations between the severity of RP and radiological se-
quelae after SBRT were found. No instances of symptomatic RF
nor other treatment-related late effects (i.e. plexopathy, rib
fractures or chest pain) were documented.
Of the 31 treated lesions, CT appearance of acute RP (6 months
or less after HT-SBRT) was classified as follows: diffuse con-
solidation in two (6.5%) lesions; patchy consolidation and GGO
in two (6.5%) lesions; diffuse GGO not observed (0%); patchy
GGO in two (6.5%) lesions. Of the 25 treated lesions, CT ap-
pearance of RF (more than 6 months after HT-SBRT) was
classified as follows: modified conventional pattern in three
(12%) lesions, mass-like pattern in four (16%) lesions, scar-like
pattern in three (12%) lesions. There was no evidence of late
lung injury in 15 (60%) patients (Table 2). The calculated
mean6 standard deviation of dosimetric parameters were as
follows: V5, 43.216 14.73%; V10, 30.396 12.15%; MLD, 5.036
1.92Gy; and contralateral MLD, 2.376 1.05Gy. No statistical
correlation was found between lung fibrosis and BED, COPD,
dosimetric or tumour parameters.
Response and disease progression
Among the 31 treated lesions, complete response (CR) occurred
in 7 (23%) cases and partial response (PR) occurred in 19 (61%)
cases with a tumour response rate of 84%. After RT, five (16%)
patients presented with local stable disease.
LF was observed in four (13%) patients. DF occurred in five
(16%) patients (lung, two patients; brain, one patient; adrenal
gland, one patient; diffuse disease, one patient).
Survival, local control and prognostic factors
At the time of the analysis, 23 patients were alive. 2 patients were
alive with pulmonary disease (distant, 1 patient; local, 1 patient),
while 21 patients had no evidence of disease. The median follow up
of the survivors was 12 months (range, 4–20 months). The tumour
Table 1. Patient (n528), tumour (n531) and radiation
treatment characteristics
Imaging findings
Number of patients/
number of lesions
(percentage of the total)
Mean age (years) 74
Range (years) 59–88
Gender
Male 22 (79)
Female 6 (21)
Chronic obstructive pulmonary disease class
GOLD 3: 30%# FEV1, 50%
predicted
21 (75)
GOLD 2: 50%# FEV1, 80%
predicted
7 (25)
Type of early stage non-small-cell lung cancer
Adenocarcinoma 15 (54)
Squamous cell 7 (25)
Unspecified 6 (21)
Maximal tumour diameter (cm)
Median 1.9
Range 0.5–3.6
Planning treatment volume volume (cm3)
Median 47.31
Range 9.4–254.5
Gross tumour volume (cm3)
Median 6.43
Range 0.65–73.7
Dose prescription (per lesions)
Peripheral lesions
Full dose
(50Gy/5 fractions)
22 (71)
Peripheral large lesions
50Gy/10 fractions 4 (13)
Central lesions
52.5Gy/7 fractions 5 (16)
Corresponding BED10 (Gy)
$100 22 (71)
,100 9 (29)
BED10, biological effective dose for a/b ratio of 10; FEV1, forced
expiratory volume in the first second; GOLD, Global Initiative for
Obstructive Lung Disease.
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response rate was 84% (CR1PR). Local control was 83% at 1 year.
On univariate analysis, GTV and PTV emerged as significant prog-
nostic factors for local control (p50.001 and p50.011, respec-
tively). Tumour-related factors such as tumour maximal diameter
(p50.05), GTV (p50.019), PTV (p50.001) had significant im-
pact on response, whereas neither patient-related nor tumour-
related or dosimetric factors impacted lung fibrosis (Table 3).
DISCUSSION
Lung lesions, either primary or metastatic, represent the para-
digm of the potential benefit achievable by SBRT because the
lung is deemed to be a parallel organ where the risk of radio-
induced normal tissue toxicity is expected to be lower when
small volumes are irradiated with large fraction sizes.28 There-
fore, SBRT is increasingly being considered as the preferred
treatment option in patients unfit for surgery.9,10 A wide range
of SBRT techniques are currently available for lung SBRT, in-
cluding 3D-CRT, IMRT, volumetric modulated arc therapy
(VMAT) and HT, and all of them could result in different pat-
terns of radiological pneumonitis owing to differences in dose
distributions. In this scenario, data on the influence of treatment
techniques on rates of clinical and radiological pneumonitis are
scarce. The largest study examining radiological changes and the
first to compare two different treatment planning techniques
(RapidArc® vs 3D-CRT) for lung SBRT comes from Palma et al29
who showed that both techniques resulted in similarly low rates
of clinical pneumonitis and similar severity and patterns of ra-
diological changes. In a dosimetric study, Chi et al30 compared
HT-based with VMAT-based SBRT for centrally located lung
lesions and found that HT appears to be superior to VMAT in
OAR sparing mainly in cases that require conformal dose
avoidance of multiple immediately adjacent OARs. However,
HT’s complex delivery of radiation dose to the target volume
and to the adjacent organs over 360° of rotation with 51 pro-
jections per rotation12 in association with the high dose per
fraction can potentially result in a large distribution of low-dose
radiation to the lung, typically composed of functional subunits
Table 2. Patterns of lung injury: early radiological findings of
acute pneumonitis and late radiological findings of radiation
fibrosis
Variables Events (%)
#6 months after hypo-HT (n5 31)
No findings 25 (80.6)
Patchy GGO 2 (6.5)
Diffuse GGO –
Patchy consolidation and GGO 2 (6.5)
Diffuse consolidation 2 (6.5)
.6 months after hypo-HT (n5 25)
No findings 15 (60.0)
Modified conventional pattern 3 (12.0)
Mass-like 4 (16.0)
Scar-like 3 (12.0)
GGO, ground-glass opacity; HT, helical tomotherapy.
Table 3. Univariate analysis for lung fibrosis and complete response (CR) (p-values)
Variables
Univariate analysis, p-value
Lung fibrosis CR
Patient-related factors
Chronic obstructive pulmonary disease (GOLD 3 vs GOLD 2) 0.626
Tumour-related factors
Maximal diameter ($23 vs ,23mm) 0.511 0.143
Maximal diameter ($20 vs ,20mm) 0.454 0.050
PTV ($50 vs ,50 cm3) 0.250 0.004
PTV ($42 vs ,42 cm3) 0.363 0.001
GTV ($7 vs ,7 cm3) 0.250 0.004
GTV ($12 vs ,12 cm3) 0.215 0.019
Tumour location (peripheral vs central) 0.542 0.312
Dosimetric parameters
V5 (,43 vs $43Gy) 0.856
V10 (,30 vs $30Gy) 0.694
MLD ($6 vs ,6Gy) 0.077
Controlateral MLD ($3 vs ,3Gy) 0.068
Biological effective dose (100 vs ,100) 0.683 0.484
GOLD, Global Initiative for Obstructive Lung Disease; GTV, gross tumour volume; MLD, mean lung dose; PTV, planning target volume; Vx, percentage
of lung volume receiving xGy.
BJR S Arcangeli et al
4 of 8 birpublications.org/bjr Br J Radiol;88:20140728
arranged in a parallel architecture (Figure 1). As such, patterns
of lung injury might be different than those observed with
conventional 3D-CRT or other SBRT techniques (Figure 2).
Understanding these changes becomes even more crucial for
patients with lung lesions, whose health is compromised by
factors that rule out surgical resection. While HT-SBRT is
gaining traction in clinical practice, few studies—often evalu-
ating small series of patients with inhomogeneous characteristics
and short follow-up—are available in the recent literature15–21
(Table 4). Owing to the risk that the helical radiation delivery
method, involving low-dose exposure of almost the entire
contralateral lung, could also affect radiation tolerance in the
high-dose regions—the so-called ‘‘bath-and-shower effect”31—
close attention in our series has been paid to V5, V10, MLD and
contralateral MLD, which were kept well below the thresholds
suggested from QUANTEC23 in order to reduce the de-
velopment of RP. In our series, the incidence of $grade 2 RP
reached 17.5%, similar to the 5–20% rates of RP reported from
several investigators for lung SBRT.32–36 Moreover, most of the
symptomatic RP was grade 2, and only one patient experienced
a grade 3 RP, less than the 6.4% incidence of grade 3 RP
reported from McGarry et al37 after lung SBRT in a similar
patient population. When investigating the predictive factors
potentially involved in the development of RP, we could not find
dosimetric or clinical factors significantly associated with
treatment-related toxicity. These findings seem in contrast to
some recent series, employing HT either in a conventional or in
a SBRT schedule for primary and metastatic lung tumours,
where cut-off values for ipsilateral38 and contralateral V5
17,39
have been proposed, and GTV was found as the only predictive
factor significantly associated with grade 5 RP.20 Guckenberger
et al40 reported the association of low-dose radiation distribu-
tion with the development of RP after SBRT, with an incidence
of RP of 18.6%. Some authors provided detailed radiological
descriptions of lung appearances after SBRT; Huang et al41 in
Figure 1. A typical dose distribution of a stereotactic plan with helical tomotherapy (axial CT images with low dose regions).
Figure 2. A case of diffuse consolidation pattern of a radio-
logical pneumonitis 3 months after stereotactic body radio-
therapy delivered with helical tomotherapy.
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a systematic review observed that acute changes post-SBRT pre-
dominantly appear as consolidation or GGOs, while late changes
often demonstrate a modified conventional pattern of fibrosis.
Trovo et al42 found that patients who developed more than grade 2
pneumonitis after SBRT showed patchy consolidation and GGO,
and patchy GGO more frequently than other patterns. In our
series, we were not able to observe a preferential pattern either in
the acute or late setting, nor a correlation between acute and late
changes over time. Interestingly, not even a correlation between
radiological appearance, the delivered dose and the tumour vol-
ume was found, in agreement with a larger series of 68 patients
(70 tumours), whose radiological changes after SBRT were in-
vestigated and correlated with treatment characteristics.43 The
aforementioned differences between our observations and some
findings in the existing literature may be owing to several factors
such as patient characteristics, sample size, SBRT treatment
technique, follow-up duration and interobserver variations. One
of the main limitations of our study is certainly related to the
relatively short follow-up that cannot exclude that structural
changes may theoretically occur later, being the fibrotic evolution
after high-dose irradiation a dynamic process that might continue
for many years.44–46 Nevertheless, when analysing the temporal
pattern of CT changes after SBRT, Dahele et al47 found that the
actuarial median time to first CT changes was 17 weeks, whereas
Hof et al48 showed that CT changes increase with dose and peak
at 16 weeks after single-fraction lung radiosurgery. Therefore, the
median follow-up of 12 months in our cohort almost entirely
covered the time course of treatment-related toxicity as well as
patterns of radiological lung injury. A further limitation of our
experience is that the scoring of CT changes after lung SBRT
herein adopted25,26 is qualitative and may be subjective. Alterna-
tive methods, such as the use of CT density changes, may rep-
resent an objective measure of lung damage because density
changes strongly correlate with histological findings of in-
flammation,49 thus allowing for a more robust dose–response
relationship based on quantitative data.50,51
CONCLUSION
Notwithstanding the retrospective nature and its intrinsic in-
herent biases, our study shows that HT-SBRT can be considered
an effective treatment with a mild toxicity profile in a medically
inoperable patient population with early stage NSCLC, provided
that careful attention is paid to low-dose exposure of normal
lung. Although a specific pattern of lung injury was not found to
be associated with this technique, patients should be carefully
followed, and long-term results are warranted.
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